Event | Placebo (N = 19) | Ambrisentan (N = 19) |
---|---|---|
Number of patients (percent) | ||
Patient with at least 1 adverse event | 17 (89.5) | 17 (89.5) |
Headache | 6 (31.58) | 6 (31.58) |
Edema | 4 (21.05) | 8 (42.11) |
Dizziness | 6 (31.58) | 0 (0)†|
Diarrhea | 2 (10.53) | 4 (21.05) |
Nausea | 3 (15.79) | 2 (10.53) |
Paresthesia | 0 (0) | 4 (21.05) |
Coronary artery disease | 3 (15.79) | 1 (5.26) |
Hypotension | 2 (10.53) | 2 (10.53) |
Epistaxis | 1 (5.26) | 3 (15.79) |
Serious adverse events* | ||
 Lower jaw fracture | 0 | 1 |
 Angina Pectoris | 1 | 0 |
 Coronary artery disease | 1 | 0 |
 Gastrointestinal infection | 1 | 0 |
 Lymphangitis | 1 | 0 |
 Raynaud | 1 | 0 |